Dihexa
Dihexa is a synthetically engineered Angiotensin IV analog originally developed to combat aggressive neurodegenerative diseases like Alzheimer's and Parkinson's. Acclaimed for having a synaptic formation potency literally 10 million times stronger than Brain-Derived Neurotrophic Factor (BDNF), Dihexa is the ultimate heavy-weight nootropic. In elite neuro-optimization contexts, it is utilized to profoundly accelerate learning, permanently repair traumatized neural pathways, and dramatically enhance raw cognitive neuroplasticity.
Quick Stats
Scientific Data
Mechanism of Action
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic peptide analog of angiotensin IV that acts on hepatocyte growth factor (HGF) receptors. It is reported to be 10^7 (ten million) times more potent than BDNF (Brain-Derived Neurotrophic Factor) at promoting spinogenesis — the formation of new dendritic spines that enable synaptic connections.
Dihexa crosses the blood-brain barrier and promotes synaptogenesis, which may enhance learning, memory, and cognitive function. It was developed at Washington State University as a potential therapeutic for neurodegenerative diseases including Alzheimer's.
Source: PMID: 23123685
Background & History
Dihexa is a potent cognitive enhancer derived from angiotensin IV, developed by Joseph Harding and John Wright at Washington State University. Published in Science (2012), it was shown to induce synaptogenesis — the formation of new synapses — with potency reportedly 7 orders of magnitude greater than BDNF in some assays. It acts via HGF/MET receptor signaling.
Research Use Cases
- ✓Cognitive decline in Alzheimer's disease and dementia (animal models)
- ✓Post-stroke cognitive recovery
- ✓Traumatic brain injury recovery
- ✓Nootropic stack component for memory and learning enhancement
Dosing Protocol
| Typical Dose | 10-40 mg/day (oral/intranasal) |
| Frequency | 1× daily |
| Half-Life | ~2-4 hours (estimated) |
Dosing Protocols
Standard Protocol
Administration
Expected Timeline
Who Is It For?
Cognitive Enhancement / Nootropic
Low10 million times more potent than BDNF at spinogenesis in vitro. Very limited human data.
Neurodegenerative Disease Research
LowDeveloped for Alzheimer's research. Powerful but data is almost entirely preclinical.
Safety & Considerations
Research peptide with very limited human data. Extremely potent — doses measured in mg/day. Oral or intranasal only. Consult a healthcare provider before use.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Long-acting — effects may persist for weeks after single dosing. Start at very low doses. Limited human safety data available. Avoid with active brain tumors.
Synergies & Common Stacks
Semax upregulates BDNF; Dihexa promotes synaptogenesis via HGF/MET. Together they support neurotrophic support from multiple angles in cognitive recovery protocols.
Cerebrolysin contains BDNF, NGF, and other neurotrophins; Dihexa promotes the synaptic infrastructure to utilize them. Potentially synergistic for neurological recovery.
Dosing Quick Reference
Frequently Asked Questions
Is Dihexa injectable?▼
How potent is Dihexa vs BDNF?▼
References
- Bhargava A et al. “"Facilitating effects of a novel angiotensin IV analogue on recovery from traumatic brain injury".” Journal of Cognitive Neuroscience (2011). PMID: 21544069
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code